This discrepancy may be explained by the differences in the skin infection models used (e.g., intradermal versus subcutaneous) and/or the methods to inhibit in vivo NET formation [e.g., PAD4-deficient mice versus deoxyribonuclease (DNase) treatment]. The gene discussed is PADI4; the disease is skin infection.